Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Ability and willingness to sign a written informed consent and /or assent (age appropriate).~2. Male or Female subjects 12 years of age or older.~3. A clinical diagnosis of interdigital tinea pedis on one or both feet characterized by clinical evidence of a tinea infection.~4. A sum of at least five (5) for signs (erythema and scaling) by the investigator on the selected target foot, and a score of at least five (5) for each symptom: pruritus (itching) and burning: and a sum of at least twelve (12) for both symptoms (pruritus and burning) by the subject on the PATSS.~5. Mycological evidence of the presence of fungi confirmed by the detection of fungal hyphae on a microscopic KOH wet mount.~6. Females of child-bearing potential must have a negative urine pregnancy test and must agree to use an effective form of contraception during the study .~7. Must be in good general health as determined by medical history and free of any disease that in the investigator's opinion might interfere with the study evaluations.~8. Must be able to communicate, be able to understand the study procedures, and be willing to comply with the study requirements.~Exclusion Criteria:~1. The presence of confluent diffuse moccasin-type tinea pedis.~2. Negative KOH microscopy test to assess presence of hyphae.~3. Onychomycosis of the toenails, involving ≥ 20% of the area of either great toenail or involvement of more than five toenails in total.~4. Concurrent tinea infection or bacterial skin infection on the feet.~5. Female subjects who are pregnant and/or nursing or planning a pregnancy during the course of the trial.~6. Recent history of or currently known to abuse drugs or alcohol.~7. History of intolerance or hypersensitivity to Econazole Nitrate, Mometasone Furoate, or other imidazole agents.~8. Presence of any other infection of the foot or other disease process that might confound the treatment evaluation.~9. Having a life-threatening condition or immunocompromised (e.g., autoimmune deficiency syndrome, cancer, unstable angina, or myocardial infarction) within the last 6 months.~10. Unable to communicate or cooperate with the investigator due to language barriers, poor mental development, or impaired cerebral function.~11. Current participation in a clinical drug research study or recent participation in a clinical trial within 30 days of Baseline.~12. Using the following medications prior to Baseline:~    1. Antipruritics, including antihistamines within 3 days (72 hours).~   2. Topical corticosteroids, antibiotics or antifungal therapies within 4 weeks.~   3. Systemic corticosteroids, antibiotics or antifungal therapies within 12 weeks.~   4. Oral terbinafine or itraconazole within 12 weeks.~   5. Immunosuppressive medication or radiation therapy within 12 weeks.~   6. Any other topical medicated topical treatments to the treatment area(s) within 7 days.~       -

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- S2G6T-1 (Type: ACTIVE_COMPARATOR): Topical cream
- S2G6T-2 (Type: ACTIVE_COMPARATOR): Topical Cream
- S2G6T-3 (Type: ACTIVE_COMPARATOR): Topical Cream
- S2G6T-4 (Type: PLACEBO_COMPARATOR): Topical Cream

Based on this trial design, predict the completion outcome and termination type (if applicable).